2 weeks Ago By Defense World Staff
Shares of Olema Pharmaceuticals, Inc. ( NASDAQ:OLMA – Get Free Report ) have been assigned an average rating of “Buy” from the six research firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation.
The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $27.00. A number of equities research analysts have recently issued reports on OLMA shares.
JPMorgan Chase & Co. cut their target price on shares of Olema Pharmaceuticals from $33.00 to $31.
00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, November 13th.
Finally, Oppenheimer reaffirmed an “outperform” rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday, August 7th. Get Our Latest Research Report on OLMA Institutional Investors Weigh In On Olema Pharmaceuticals Olema Pharmaceuticals Price Performance NASDAQ OLMA opened at $9.
72 on Wednesday. The company has a market capitalization of $556.96 million, a price-to-earnings ratio of -4.
44 and a beta of 2.02. Olema Pharmaceuticals has a 12 month low of $7.
68 and a 12 month high of $16.77. The company’s fifty day moving average price is $11.
49 and its two-hundred day moving average price is $11.90. Olema Pharmaceuticals Company Profile ( Get Free Report Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.
Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. Featured Articles Five stocks we like better than Olema Pharmaceuticals Consumer Staples Stocks, Explained Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor Dividend Capture Strategy: What You Need to Know Why Warren Buffett Is Selling: A Look at His Latest Market Moves Quiet Period Expirations Explained Why Amazon Shares May Never Trade Below $200 Again Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
